A retrospective study showed that women with benign uterine disease who took GLP-1 agonists along with progestins had a significantly lower risk of endometrial cancer compared to women treated with progestins alone.[1] The study brought more good news about GLP-1 agonists and cancer risk.[1] A new study led by Case Western Reserve University School of Medicine found that GLP-1 agonists reduce the risk of obesity-related cancers.[1] In this study of patients with type 2 diabetes without cancer at baseline, GLP-1RA use was associated with a lower risk of 10 of 13 obesity-related cancers compared with insulin.[1] There was no association between GLP-1RA and postmenopausal breast or thyroid cancer.[1] The risk of stomach cancer was reduced by 27%, but this was not statistically significant.[1] Compared with metformin, GLP-1RAs were associated with a reduced risk of colorectal cancer, gallbladder cancer, and meningiomas, although not statistically significant, but an increased risk of kidney cancer.[1] Researchers recommend continuous monitoring of patients taking GLP-1RAs.[1]